Perioperative therapy improves gastro-oesophageal cancer survival

Tom Waddell and David Cunningham

A randomised phase III study has reported significant improvements in RO resection rate and overall survival associated with perioperative cisplatin and 5-fluorouracil treatment compared with surgery alone in patients with gastro-oesophageal adenocarcinoma. These data support the results of the randomised phase III MAGIC study that reported a 13% five-year survival benefit from perioperative chemotherapy.

Download full article

Be the first to comment

Leave a Reply

Your email address will not be published.